Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefadroxil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | SLC15A2 | Q16348 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 1.00 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.85 |
| ▸ | HPGD | P15428 | 3/20 | 0.85 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.85 |
| ▸ | BLM | P54132 | 2/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.85 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.85 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.85 |
| ▸ | HTR2B | P41595 | 1/20 | 0.85 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.75 |
| ▸ | DRD2 | P14416 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefadroxil SCHEMBL6438517 | 1.00 | MAPT (1.00) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL16072813 | 1.00 | MAPT (1.00) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL3984782 | 1.00 | MAPT (1.00) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL3984780 | 1.00 | MAPT (1.00) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL19123520 | 1.00 | MAPT (1.00) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL151320 | 1.00 | MAPT (1.00) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL9650920 | 1.00 | MAPT (1.00) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL13698957 | 1.00 | MAPT (1.00) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL9807365 | 0.99 | MAPT (0.98) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL1821440 | 0.99 | MAPT (0.98) | MAPTHSD17B10KMT2AMEN1SLC15A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 310 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150320694-A1 | MUCOADHESIVE NANOPARTICLE DELIVERY SYSTEM | UNIVERSITY OF WATERLOO (CA) | 2015-11-12 | — | — | US | claimed |
| EP-2863892-A1 | MUCOADHESIVE NANOPARTICLE DELIVERY SYSTEM | Gu, Frank (CA) | 2015-04-29 | — | — | EP | claimed |
| WO-2013188979-A1 | MUCOADHESIVE NANOPARTICLE DELIVERY SYSTEM | GU FRANK (CA) | 2013-12-27 | — | — | WO | claimed |
| WO-2009131692-A1 | SUBSTRATES FOR DELIVERY OF PHYSIOLOGICALLY ACTIVE AGENTS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2009-10-29 | — | — | WO | claimed |
| US-12622973-B2 | Rejuvenation of CAR T cell | PURDUE RESEARCH FOUNDATION (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260007746-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISORDERS | SACKSTEIN ROBERT (US) | 2026-01-08 | — | — | US | disclosed |
| US-12497461-B2 | Human NTCP-binding antibody capable of inhibiting infection of hepatitis B virus (HBV) to human hepatocytes | RIKEN (JP) | 2025-12-16 | — | — | US | disclosed |
| EP-4637744-A1 | ADIPONECTIN ALONE OR IN COMBINATION WITH EXTRACORPOREAL PHOTOPHERESIS (ECP) FOR IMMUNE RELATED ADVERSE EVENTS OF IMMUNE CHECKPOINT INHIBITORS | Therakos Development Limited (IE) | 2025-10-29 | — | — | EP | disclosed |
| US-12383606-B2 | Short chain ceramide-based lipids and uses thereof | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-08-12 | — | — | US | disclosed |
| US-12296016-B2 | Ceramide-like lipid-based delivery vehicles and uses thereof | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-05-13 | — | — | US | disclosed |
| US-12274740-B2 | Microbiome protection from oral antibiotics | THERIVA BIOLOGICS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-12178917-B2 | Beta-lactamase formulations and uses thereof | THERIVA BIOLOGICS, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| WO-1998046213-A1 | CEFADROXIL MONOHYDRATE TABLET FORMULATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
| US-5409710-A | Foam cell drug delivery | ENDOCON, INC. (US) | 1995-04-25 | — | — | US | disclosed |
| WO-1994023706-A1 | FOAM CELL DRUG DELIVERY | ENDOCON, INC. (US) | 1994-10-27 | — | — | WO | disclosed |
| EP-0584220-A1 | ENGINEERING THE LOCAL INFLAMMATORY RESPONSE AS A MEANS OF CONTROLLED RELEASE DRUG DELIVERY | ENDOCON, INC. (US) | 1994-03-02 | — | — | EP | disclosed |
| WO-1992020325-A1 | ENGINEERING THE LOCAL INFLAMMATORY RESPONSE AS A MEANS OF CONTROLLED RELEASE DRUG DELIVERY | ENDOCON, INC. (US) | 1992-11-26 | — | — | WO | disclosed |
| US-5037810-A | Medical application for heparin and related molecules | SALIBA JR MICHAEL J (US) | 1991-08-06 | — | — | US | disclosed |
| US-4879282-A | Medical application for heparin and related molecules | SALIBA JR MICHAEL J (US) | 1989-11-07 | — | — | US | disclosed |
| WO-1988006840-A1 | MEDICAL APPLICATION FOR HEPARIN AND RELATED MOLECULES | SALIBA MICHAEL J JR (US) | 1988-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12274740-B2 | Microbiome protection from oral antibiotics | TLR5, FABP2, TLR9 | MAPT 2441/4885HSD17B10 648/4885KMT2A 1665/4885 |
| US-12622973-B2 | Rejuvenation of CAR T cell | CD69, CD40LG, CD47 | MAPT 552/4885HSD17B10 4085/4885KMT2A 3559/4885 |
| US-20260007746-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISORDERS | CD44, SELL, ICAM1 | MAPT 2558/4885HSD17B10 840/4885KMT2A 3629/4885 |
| US-20150320694-A1 | MUCOADHESIVE NANOPARTICLE DELIVERY SYSTEM | MUC1, CD63, TSG101 | MAPT 3406/4885HSD17B10 4404/4885KMT2A 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.